Clearmind Medicine (CMND) Regains Nasdaq Minimum Equity Compliance

Rhea-AI Filing Summary

Clearmind Medicine Inc., a foreign private issuer, submitted a Form 6-K that furnishes a press release titled “Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement.” This indicates the company reports it has regained compliance with that specific Nasdaq stockholders’ equity standard.

The press release is filed as Exhibit 99.1 and is incorporated by reference into Clearmind Medicine’s existing registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695). The report is signed on behalf of the company by Chief Executive Officer Adi Zuloff-Shani.

Positive

• Regained Nasdaq stockholders’ equity compliance, as stated in the press release title, which indicates the company is again meeting that specific Nasdaq equity standard.

Negative

• None.

Insights

Capital markets and listing standards analyst

Clearmind reports it has regained compliance with a key Nasdaq equity standard.

Clearmind Medicine states that it has “successfully regains compliance with Nasdaq’s minimum stockholders’ equity requirement,” as reflected in the title of the press release furnished with this report. That phrase signals the company is again meeting Nasdaq’s specified minimum level of stockholders’ equity, an important quantitative standard for continued listing.

For shareholders, being in compliance with a major exchange’s stockholders’ equity requirement is generally viewed more favorably than falling below it, because it aligns the company with that exchange’s ongoing eligibility criteria. The company also incorporates this press release by reference into multiple Form F-3 and Form S-8 registration statements, ensuring that the updated compliance status is formally included in those offering-related documents.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: December 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on December 12, 2025, titled “Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement”.

The press release attached to this Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: December 12, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

FAQ

What did Clearmind Medicine (CMND) report in its latest Form 6-K?

Clearmind Medicine filed a Form 6-K reporting that it furnished a press release titled “Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement.”

What is the subject of Clearmind Medicine’s December 12, 2025 press release?

The press release, titled “Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement”, states that the company has regained compliance with Nasdaq’s minimum stockholders’ equity standard.

How is the press release used in Clearmind Medicine’s existing SEC registration statements?

The press release filed as Exhibit 99.1 is incorporated by reference into Clearmind Medicine’s registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).

What type of SEC filer is Clearmind Medicine (CMND)?

Clearmind Medicine is described as a foreign private issuer submitting a Report of Foreign Private Issuer on Form 6-K under Rules 13a-16 or 15d-16 of the Exchange Act.

Who signed the Form 6-K for Clearmind Medicine and in what capacity?

The Form 6-K was signed on behalf of Clearmind Medicine by Adi Zuloff-Shani, who is identified as the company’s Chief Executive Officer.

Where is Clearmind Medicine’s principal executive office located?

The company’s principal executive offices are listed at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.